Arch Therapeutics, Inc., operates as a biotechnology company in the United States. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery, trauma, and interventional care. Its primary product candidate is AC5 Devices, a synthetic biocompatible peptides that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone617-431-2313
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees9
OptionableNot Optionable
Arch Therapeutics (OTCMKTS:ARTH) Frequently Asked Questions
What is Arch Therapeutics' stock symbol?
Arch Therapeutics trades on the OTCMKTS under the ticker symbol "ARTH."
How were Arch Therapeutics' earnings last quarter?
Arch Therapeutics Inc (OTCMKTS:ARTH) announced its quarterly earnings results on Tuesday, May, 2nd. The biotechnology company reported ($0.01) EPS for the quarter, hitting analysts' consensus estimates of ($0.01). View Arch Therapeutics' Earnings History.
When is Arch Therapeutics' next earnings date?
What price target have analysts set for ARTH?
4 brokers have issued twelve-month target prices for Arch Therapeutics' stock. Their predictions range from $3.00 to $3.00. On average, they anticipate Arch Therapeutics' share price to reach $3.00 in the next year. This suggests a possible upside of 659.5% from the stock's current price. View Analyst Price Targets for Arch Therapeutics.
What is the consensus analysts' recommendation for Arch Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arch Therapeutics in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arch Therapeutics.
Has Arch Therapeutics been receiving favorable news coverage?
Media stories about ARTH stock have trended negative this week, according to InfoTrie. The research group identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Arch Therapeutics earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future.
Who are some of Arch Therapeutics' key competitors?
Some companies that are related to Arch Therapeutics include Vapotherm (VAPO), Neuronetics (STIM), Pulse Biosciences (PLSE), Nuvectra (NVTR), Cytosorbents (CTSO), Liquidia Technologies (LQDA), T2 Biosystems (TTOO), RenovaCare (RCAR), Sensus Healthcare (SRTS), RA Medical Systems (RMED), STRATA Skin Sciences (SSKN), Endologix (ELGX), iCAD (ICAD), Alphatec (ATEC) and Apollo Endosurgery (APEN).
Who are Arch Therapeutics' key executives?
Arch Therapeutics' management team includes the folowing people:
- Dr. Terrence W. Norchi, Chairman, Pres, CEO, Sec. & Director (Age 54)
- Mr. Richard E. Davis, CFO & Treasurer (Age 61)
- Dr. Avtar S. Dhillon, Bus. Advisor (Age 58)
- Mr. Rutledge Ellis-Behnke, Co-Founder & Scientific Advisor
- Dr. Steven A. Kates Ph.D., VP of Technology
How do I buy shares of Arch Therapeutics?
Shares of ARTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Arch Therapeutics' stock price today?
One share of ARTH stock can currently be purchased for approximately $0.3950.
How big of a company is Arch Therapeutics?
Arch Therapeutics has a market capitalization of $64.07 million. The biotechnology company earns $-4,810,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Arch Therapeutics employs 9 workers across the globe.
What is Arch Therapeutics' official website?
How can I contact Arch Therapeutics?
Arch Therapeutics' mailing address is 235 WALNUT STREET SUITE 6, FRAMINGHAM MA, 01702. The biotechnology company can be reached via phone at 617-431-2313 or via email at [email protected]
MarketBeat Community Rating for Arch Therapeutics (OTCMKTS ARTH)
MarketBeat's community ratings are surveys of what our community members think about Arch Therapeutics and other stocks. Vote "Outperform" if you believe ARTH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARTH will underperform the S&P 500 over the long term. You may vote once every thirty days.
